BeOne Medicines (ONC) Gross Profit (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Gross Profit data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Gross Profit rose 41.37% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $5.1 billion, a 43.11% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 45.34% from the prior year.
• Gross Profit for Q1 2026 stood at $1.3 billion, down from $1.4 billion in the prior quarter.
• Over the last five years, Gross Profit for ONC reached as high as $1.4 billion in Q4 2025 and fell as low as $241.4 million in Q1 2022.
• Historically, Gross Profit has averaged $732.1 million across 5 years, with a median of $685.0 million in 2023.
• On a YoY basis, Gross Profit climbed as much as 137.76% in 2022 and fell as far as 57.89% in 2022.
• Year by year, Gross Profit stood at $306.6 million in 2022, then soared by 72.41% to $528.6 million in 2023, then jumped by 82.99% to $967.3 million in 2024, then surged by 40.16% to $1.4 billion in 2025, then declined by 0.7% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.